PBS reports President Donald Trump selected Dr. Heidi Overton, a White House Domestic Policy Council aide, to lead the FDA

The appointment would place a medical doctor and Domestic Policy Council deputy director in charge of the federal Food and Drug Administration, if confirmed through the administration’s formal process.

2 min readEditor-approved Apex article

President Donald Trump has selected White House aide Dr. Heidi Overton to lead the Food and Drug Administration, according to PBS NewsHour Politics. PBS said Overton is a medical doctor and serves as a deputy director of the White House Domestic Policy Council, and that she has worked on several of the president’s second-term health initiatives.

PBS reported the selection as part of President Trump’s health and regulatory agenda. The report did not describe a specific date for when Overton would begin the FDA role, nor did it provide details of any formal nomination or appointment paperwork tied to the selection.

Overton’s background described by PBS includes medical training and experience inside the Domestic Policy Council, a White House office that coordinates policy development across agencies. PBS also said she has worked on initiatives associated with President Trump’s health priorities during his second term.

The FDA commissioner role oversees a wide range of responsibilities, including regulation of prescription drugs and biologics, medical devices, food safety, and public health risk management. A change in leadership can affect how the agency sets priorities for enforcement, oversight, and rulemaking, though the specific practical impact would depend on the administration’s directives after an official appointment.

PBS’s report comes without immediate official confirmation from the White House or an FDA release in the available record. As of now, an official announcement, nomination documentation, or Federal Register notice would be needed to verify the selection and the timing under applicable appointment procedures.

If the selection moves forward, Overton would be expected to assume the FDA’s day-to-day leadership responsibilities and represent the agency in senior executive-branch health policy discussions. The next step for the public record would be an official White House or FDA communication and any required documentation that establishes the final authority and effective date.

Why It Matters

FDA leadership influences the administration and execution of federal oversight for drugs, biologics, medical devices, and other regulated products.
A new commissioner can shape enforcement posture and regulatory priorities, depending on direction from the White House and the agency’s internal agenda.
Because PBS’s report does not include an official confirmation in the available record, the timing and legal status of any appointment depends on the administration’s formal next steps.
The shift would move a White House Domestic Policy Council deputy director into an agency head role that interfaces with public health and regulatory compliance outcomes.

Sources

Key Facts

PBS NewsHour Politics reported that President Donald Trump selected Dr. Heidi Overton to lead the U.S. Food and Drug Administration.
PBS described Overton as a medical doctor and deputy director of the White House Domestic Policy Council.
PBS said Overton has worked on several of President Trump’s second-term health initiatives.
The available record does not include an official White House or Federal Register confirmation of the selection’s final status or effective date.